This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| International Gaucher Registry | |
|---|---|
| Name | International Gaucher Registry |
| Formation | 1990s |
| Type | Medical registry |
| Purpose | Clinical data collection for Gaucher disease |
| Headquarters | International |
| Region served | Worldwide |
International Gaucher Registry The International Gaucher Registry is a global clinical database for Gaucher disease linking patient data, treatment outcomes, and research collaborations to support clinical care and scientific research. It connects clinicians, pharmaceutical companies, academic institutions, patient advocacy organizations, and regulatory agencies to aggregate longitudinal data on genotype, phenotype, and therapeutic response. The Registry interfaces with multi-center networks, rare disease consortia, and public health initiatives to inform clinical guidelines, regulatory approvals, and health technology assessments.
The Registry collects standardized clinical, genetic, biochemical, and therapeutic data to characterize manifestations of Gaucher disease across populations tracked by centers such as Mayo Clinic, Johns Hopkins Hospital, Mount Sinai Health System, Great Ormond Street Hospital, Charité – Universitätsmedizin Berlin and others. It collaborates with pharmaceutical sponsors including Genzyme, Shire plc, Takeda Pharmaceutical Company Limited, Pfizer, and clinical trial networks like European Organisation for Research and Treatment of Cancer and National Institutes of Health programs. Stakeholders include patient organizations such as National Gaucher Foundation, Gaucher Association UK, Spanish Federation of Rare Diseases, and international bodies including World Health Organization and European Medicines Agency.
The Registry originated amid advances in enzyme replacement therapy pioneered by researchers at institutions like Scripps Research, Boston Children's Hospital, University of California, San Francisco, and companies such as Genzyme during the 1990s. Early development involved collaborations with geneticists from Harvard Medical School, University of Cambridge, and Yale School of Medicine to catalog GBA mutations identified alongside projects like the Human Genome Project. Over time the Registry expanded through partnerships with networks including Orphanet, Global Alliance for Genomics and Health, and national health systems like NHS England to incorporate electronic health record data and natural history studies.
Primary objectives include describing natural history, evaluating long-term efficacy and safety of therapies approved by agencies such as U.S. Food and Drug Administration, European Medicines Agency, and Health Canada, and supporting post-marketing surveillance initiatives coordinated with organizations like International Society for Pharmacoeconomics and Outcomes Research and World Health Organization. Governance typically involves oversight boards comprising clinicians from Cleveland Clinic, Karolinska Institutet, Stanford University School of Medicine, patient representatives from Global Genes, and industry liaisons, with policies aligned to standards from bodies like Council for International Organizations of Medical Sciences and International Committee of Medical Journal Editors.
Data management employs standardized case report forms, genotype repositories, and biobanks linked to laboratories such as Mayo Clinic Laboratories, Laboratory Corporation of America, and academic core facilities at Broad Institute and Wellcome Sanger Institute. Clinical variables include GBA variants catalogued alongside registries like ClinVar and gnomAD, endpoints used in trials at AstraZeneca and Novartis, and imaging biomarkers comparable to measures used in Radiological Society of North America studies. Data harmonization aligns with initiatives like Observational Health Data Sciences and Informatics and privacy frameworks from European Data Protection Board and U.S. Department of Health and Human Services.
The Registry has supported publications in journals and platforms linked to institutions such as The Lancet, New England Journal of Medicine, Nature Medicine, and specialty journals affiliated with American Society of Hematology and European Society of Human Genetics. Research outcomes include genotype-phenotype correlation studies involving collaborators from University of Toronto, Weill Cornell Medicine, Imperial College London, and pharmacovigilance reports informing label updates by U.S. Food and Drug Administration and European Medicines Agency. Meta-analyses and consensus guidelines produced with societies like International Society on Thrombosis and Haemostasis and American College of Medical Genetics and Genomics draw on longitudinal Registry data.
Enrollment pathways engage referral centers such as Penn Medicine, University College London Hospitals, and regional clinics connected to advocacy groups like Rare Diseases UK and Genetic Alliance. Consent processes coordinate with institutional review boards at universities like Yale University, Columbia University, and University of Melbourne. Participants include adults and pediatric cohorts tracked in studies with collaborators from Children's Hospital of Philadelphia, Baylor College of Medicine, and population registries used by Centers for Disease Control and Prevention for rare disease surveillance.
Ethical oversight follows principles endorsed by World Medical Association and regulatory guidance from European Data Protection Supervisor and U.S. Office for Human Research Protections. Legal agreements with partners like International Federation of Pharmaceutical Manufacturers & Associations and data sharing modeled on frameworks from Global Alliance for Genomics and Health address cross-border transfer, de-identification, and secondary use. Privacy safeguards incorporate standards promoted by Health Level Seven International and security audits aligned with practices at National Institute of Standards and Technology and institutional data governance teams.
Category:Medical registries Category:Rare disease patient registries Category:Gaucher disease